Nature Communications (Oct 2018)

CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response

  • Karol Szlachta,
  • Cem Kuscu,
  • Turan Tufan,
  • Sara J. Adair,
  • Stephen Shang,
  • Alex D. Michaels,
  • Matthew G. Mullen,
  • Natasha Lopes Fischer,
  • Jiekun Yang,
  • Limin Liu,
  • Prasad Trivedi,
  • Edward B. Stelow,
  • P. Todd Stukenberg,
  • J. Thomas Parsons,
  • Todd W. Bauer,
  • Mazhar Adli

DOI
https://doi.org/10.1038/s41467-018-06676-2
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 13

Abstract

Read online

Predicting the response to chemotherapy is a major goal of cancer research. Here the authors use CRISPR knockout screens in pancreatic ductal adenocarcinoma cells to identify deletions synergistic with MEK inhibitors.